Attralus welcomes Dr. Alex Denner to its Board and announces $116m Series B financing led by Logos Capital

– USA, CA –  Attralus, Inc., a clinical-stage biopharmaceutical company developing transformative medicines to improve the lives of patients with systemic amyloidosis, today announced that it has closed a $116 million Series B financing round led by Logos Capital alongside Janus Henderson Investors, Redmile Group, Samsara BioCapital, Sarissa Capital Management, Surveyor Capital, Vivo Capital, and founding investor, venBio Partners, also participating.

Attralus also announced the appointment of Dr. Alex Denner (Ph.D.) to its board of directors, joining Jake Bauer who has served on the board as an independent director since July 2021.

Mr. Bauer is a seasoned biopharmaceutical industry executive who most recently served as Chief Business Officer of MyoKardia, Inc., before MyoKardia, Inc.’s acquisition by Bristol Meyers Squibb.

Dr. Denner is a founding partner and chief investment officer of Sarissa Capital Management LP. From 2006 to 2011, Dr. Denner served as a senior managing director at Icahn Capital L.P. Before that, he served as a portfolio manager at Viking Global Investors and Morgan Stanley Investment Management. Dr. Denner serves on the board of directors of Biogen Inc. and Ironwood Pharmaceuticals, Inc. In the last five years, Dr. Denner has served as chair of the board of directors of Ariad Pharmaceuticals, Inc., and The Medicines Company, as well as a member of the board of directors of Bioverativ Inc.

“We are delighted to welcome Dr. Denner to our Board of Directors, as we accelerate development of our pipeline and continue to grow our business,” said Board Chairman, Dr. Corey Goodman.

Proceeds from the financing will be used to prepare the advancement of Attralus’ PAR therapeutics into clinical trials. The first PAR therapeutic, AT-03, is expected to begin a Phase 1 biodistribution study in systemic amyloidosis patients. Additionally, the company plans to advance the AT-01 clinical program, an amyloid-specific imaging radiotracer for the diagnosis of systemic amyloidosis. The funding will also enable the company to expand its team and infrastructure to support future growth.

“This financing from a world-class syndicate of investors with deep expertise and experience in the life science space reflects the recognition of the strong potential of our pipeline of innovative pan-amyloid removal therapeutics to bring a new treatment approach to patients with systemic amyloidosis,” said CEO, Mark Timneys. “With this support, we will accelerate our strategy to advance our PAR therapeutic programs into clinical trials along with the world’s first amyloidosis-specific diagnostic imaging agent.”

“Attralus offers unique value by developing amyloidosis therapies capable of broadly removing existing amyloid deposits, going beyond current treatments that slow progression but do not remove amyloid from organs,” said Dr. Graham Walmsley and Dr. Arsani William of Logos Capital. “At Logos, our mission is to invest in companies capable of significantly advancing the standard of care for patients. We are honored to support Attralus in pursuit of that goal.”

About Attralus

Attralus is a clinical-stage biopharmaceutical company focused on creating transformative medicines to improve the lives of patients with systemic amyloidosis. The company’s proprietary pan-amyloid removal therapeutics are designed to directly bind to and remove toxic amyloid in organs and tissues. By targeting the universal disease-causing pathology in systemic amyloidosis diseases, PAR therapeutics have the potential to treat and reverse disease in patients with all types and stages of systemic amyloidosis. Attralus was founded by scientific experts in the field of amyloidosis and the company is headquartered in South San Francisco.

For more information:

- DisclaimerNews, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.